Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Warning Letter
  6. /
  7. Chromatography Institute of America dba Compounder’s International Analytical Laboratory
WARNING LETTER
•Chromatography Institute of America dba Compounder’s International Analytical Laboratory•March 5, 2025

Chromatography Institute of America dba Compounder’s International Analytical Laboratory – FDA Warning Letter, Mar 5, 2025

Record Details

The FDA issued a warning letter to Chromatography Institute of America, operating as Compounder’s International Analytical Laboratory, following an inspection from February 24 to March 5, 2025. The inspection revealed significant violations of Current Good Manufacturing Practice (CGMP) requirements for finished pharmaceuticals and active pharmaceutical ingredients (APIs), leading to the classification of the company"s drugs as adulterated under the Federal Food, Drug, and Cosmetic Act.

Key violations included inadequate laboratory control mechanisms, insufficient investigations into sterility test failures, and a lack of adequate Quality Unit oversight. Specifically, the firm failed to ensure the reliability of microbiological testing results, did not conduct proper investigations into sterility failures, and lacked comprehensive oversight from its Quality Unit. The company’s response to these issues was deemed inadequate by the FDA, as it did not provide sufficient evidence or corrective actions to address the identified deficiencies.

The FDA requires the company to conduct a comprehensive assessment of its global manufacturing operations to ensure compliance with CGMP standards. The firm must also inform its clients of any out-of-specification results or significant issues encountered during drug testing. The FDA emphasized the importance of operating in full compliance with CGMP to maintain the quality, safety, and efficacy of drugs tested for clients.

During the inspection, the company indicated plans to cease operations, but the FDA noted inconsistencies in the firm"s responses regarding this decision. The FDA expects a detailed response addressing the identified issues and corrective actions.

Company
Chromatography Institute of America dba Compounder’s International Analytical Laboratory
Inspection date
March 5, 2025
Product type
Drugs
Office
Center for Drug Evaluation and Research
People
  • Francis Godwin (Director)
  • Johnetta F. Walters
View Company Profile

ID · f689630b-7418-41b7-87f2-9c7f07b9b786

Violation Codes3
FD&C Act 501(a)(2)(B)21 U.S.C. 351(a)(2)(B)FD&C Act 503B

Full citation text and observation details available on the Dashboard.

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Chromatography Institute of America dba Compounder’s International Analytical Laboratory
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.